Timothy A Chan Selected Research

Class 2 Receptor-Like Protein Tyrosine Phosphatases

1/2015	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
8/2014	Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
6/2009	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy A Chan Research Topics

Disease

133	Neoplasms (Cancer) 08/2022 - 03/2002
24	Glioma (Gliomas) 01/2020 - 01/2007
15	Glioblastoma (Glioblastoma Multiforme) 01/2019 - 07/2005
14	Melanoma (Melanoma, Malignant) 01/2019 - 12/2014
12	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 03/2002
11	Brain Neoplasms (Brain Tumor) 05/2019 - 02/2012
10	Carcinoma (Carcinomatosis) 01/2022 - 08/2012
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2016
8	Carcinogenesis 01/2020 - 03/2002
6	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2012
5	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2011
5	Lung Neoplasms (Lung Cancer) 06/2019 - 04/2015
5	Squamous Cell Carcinoma of Head and Neck 01/2019 - 11/2011
5	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 05/2012
4	Thyroid Neoplasms (Thyroid Cancer) 01/2022 - 09/2013
3	Adenocarcinoma 01/2020 - 06/2014
3	Head and Neck Neoplasms (Head and Neck Cancer) 06/2019 - 11/2011
3	Disease Progression 01/2019 - 02/2012
2	COVID-19 01/2022 - 01/2021
2	Microsatellite Instability 10/2021 - 01/2019
2	Kidney Neoplasms (Kidney Cancer) 06/2021 - 01/2021
2	Infections 01/2021 - 01/2020
2	Communicable Diseases (Infectious Diseases) 11/2019 - 11/2017
2	Cysts 01/2019 - 02/2016
2	Salivary Gland Neoplasms (Salivary Gland Cancer) 10/2017 - 07/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 02/2012
2	Parkinson Disease (Parkinson's Disease) 04/2010 - 01/2010
2	Colonic Neoplasms (Colon Cancer) 06/2006 - 03/2002
1	Inflammation (Inflammations) 10/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

35	Immune Checkpoint InhibitorsIBA 04/2022 - 12/2014
23	Biomarkers (Surrogate Marker)IBA 10/2022 - 06/2009
15	DNA (Deoxyribonucleic Acid)IBA 06/2021 - 09/2007
9	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2015
8	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2010
8	AntigensIBA 12/2021 - 02/2016
8	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2020 - 02/2012
8	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 02/2012
6	InterferonsIBA 01/2022 - 08/2015
6	HLA Antigens (Human Leukocyte Antigens)IBA 12/2021 - 01/2018
6	Pharmaceutical PreparationsIBA 05/2021 - 10/2012
6	ChromatinIBA 01/2020 - 07/2013
5	pembrolizumabIBA 01/2022 - 04/2015
5	Biological ProductsIBA 11/2021 - 07/2009
5	Peptides (Polypeptides)IBA 11/2019 - 02/2015
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 02/2015
4	EnzymesIBA 01/2019 - 05/2013
4	Bevacizumab (Avastin)FDA Link 10/2018 - 02/2013
4	IpilimumabIBA 11/2017 - 12/2014
4	Messenger RNA (mRNA)IBA 01/2017 - 01/2015
4	Protein Tyrosine PhosphatasesIBA 06/2014 - 10/2009
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 01/2018
3	MethyltransferasesIBA 10/2018 - 02/2012
3	Class 2 Receptor-Like Protein Tyrosine PhosphatasesIBA 01/2015 - 06/2009
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2014 - 06/2009
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 06/2006 - 03/2002
2	Interleukin-15 (Interleukin 15)IBA 08/2022 - 01/2022
2	EpitopesIBA 01/2022 - 11/2017
2	AntibodiesIBA 01/2022 - 12/2014
2	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2022 - 08/2015
2	Granzymes (Granzyme)IBA 01/2022 - 01/2019
2	Small Cytoplasmic RNAIBA 10/2021 - 01/2021
2	5'-N-methylcarboxamideadenosineIBA 01/2020 - 10/2017
2	VaccinesIBA 01/2020 - 03/2015
2	ParaffinIBA 12/2018 - 08/2012
2	Formaldehyde (Formol)FDA Link 12/2018 - 08/2012
2	Tyrosine Kinase InhibitorsIBA 12/2018 - 06/2014
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2017 - 01/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2014 - 11/2011
2	delta Opioid Receptors (delta Opioid Receptor)IBA 05/2014 - 02/2012
2	ErbB Receptors (EGF Receptor)IBA 05/2014 - 11/2011
2	Cetuximab (Erbitux)FDA Link 05/2014 - 11/2011
2	Histones (Histone)IBA 04/2014 - 02/2012
2	Azacitidine (5 Azacytidine)FDA Link 04/2014 - 10/2013
2	Decitabine FDA Link 04/2014 - 10/2013
2	alpha-hydroxyglutarateIBA 10/2013 - 02/2012
2	CateninsIBA 05/2013 - 03/2013
2	Calcibiotic Root Canal SealerIBA 08/2012 - 06/2009
2	Tyrosine (L-Tyrosine)FDA Link 02/2012 - 06/2009
2	Tumor Biomarkers (Tumor Markers)IBA 01/2012 - 09/2007
2	Cyclin EIBA 04/2010 - 01/2010
2	beta CateninIBA 06/2006 - 06/2002
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2022
1	Serum AlbuminIBA 04/2022
1	AlbuminsIBA 04/2022
1	CytokinesIBA 04/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	NAD (NADH)IBA 01/2022
1	AndrogensIBA 01/2022
1	Androgen Antagonists (Antiandrogens)IBA 01/2022
1	IodineIBA 01/2022
1	Lysine (L-Lysine)FDA Link 01/2022

Therapy/Procedure

45	Therapeutics 01/2022 - 01/2013
42	Immunotherapy 01/2022 - 02/2015
22	Radiotherapy 01/2021 - 07/2005
8	Drug Therapy (Chemotherapy) 01/2022 - 01/2012
2	Aftercare (After-Treatment) 01/2021 - 07/2009
2	Chemoradiotherapy 01/2021 - 01/2019
2	Nephrectomy 01/2020 - 01/2019
2	Brachytherapy 01/2007 - 07/2005